Pink SheetThe Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai
ScripThe pharmaceutical industry in Europe has criticized the Council of the EU’s adoption of a package of legislative reforms for medicines, claiming that the continent’s innovation-unfriendly environment
ScripWhen clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around
ScripAstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change